Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 5 Feb 2020 |
| CORRECTION: Orion Group Financial Statement Release for 2019 - wrong dividend payment date | 5 Feb 2020 |
| Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2020 AGM of Orion Corporation | 22 Jan 2020 |
| 228,223 Orion Corporation A shares converted into B shares | 21 Jan 2020 |
| 33,944 Orion Corporation A shares converted into B shares | 18 Dec 2019 |